Trials / Completed
CompletedNCT02632435
Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment.
A Pragmatic Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment OTT 15-06 A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Trastuzumab Study).
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Ottawa Hospital Research Institute · Academic / Other
- Sex
- Female
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
In the REaCT-Vascular Access Trastuzumab study (REaCT-VA), the investigator will use a novel method to allow comparisons of established standard of care vascular access strategies using the "integrated consent model" as part of a pragmatic clinical trial. The investigator wishes to address a non-pharmacologic issue regarding standard of care vascular access devices. Peripherally inserted central catheters (PICC lines) versus subcutaneously implanted devices (PORTs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | PICC | Participants will be randomized to a PICC for vascular access during chemotherapy. |
| DEVICE | PORT | Participants will be randomized to a PORT for vascular access during chemotherapy |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2019-05-01
- Completion
- 2019-05-01
- First posted
- 2015-12-16
- Last updated
- 2019-09-06
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02632435. Inclusion in this directory is not an endorsement.